-
Impax Laboratories (IPXL): 5 Things The New CEO Could Announce - RBC
-
Impax Laboratories (IPXL) Awarded Positive Decision in LCI Zomig Suit - RBC
-
Impax Laboratories (IPXL) PT Lowered to $10 at RBC Capital
-
Impax Laboratories (IPXL): Raising 4Q EPS 33% Ahead Of Earnings - RBC
-
Impax Laboratories (IPXL): Cutting PT To $18 On Teva Price Cuts - RBC
-
RBC Capital Cuts Price Target on Impax Laboratories (IPXL) Following Unexpected 2Q Miss
-
Notable Mergers and Acquisitions 6/21: (IPXL) (OSIS)/(ASEI) (TCEHY) (PHG)
-
Notable Mergers and Acquisitions 6/21: (IPXL) (OSIS)/(ASEI) (TCEHY) (PHG)
-
Impax Laboratories (IPXL) to Acquire Generics Portfolio from Teva, Allergan; Updates FY16 Outlook
-
Impax Signs Definitive Agreements to Acquire Generic Products
-
Impax's (IPXL) Guidance Disappoints But Excludes Hidden Opportunity - RBC
-
Impax Laboratories (IPXL) Prices Aggregate $500M Conv. Notes Offering
-
Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes
-
Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes
-
RBC Capital Starts Impax Laboratories (IPXL) at Sector Perform
-
RBC Capital Downgrades Impax Laboratories (IPXL) to Sector Perform
-
RBC Capital Starts Impax Laboratories (IPXL) at Outperform
-
Notable Analyst Rating Changes 09/14: HOLX, MRX, TOT Upgraded; CPB, XOM, NWL, IPXL Downgraded
-
Daily State of the Markets: Breaking on Through?
-
Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded

